JERUSALEM, Sept 13 (Reuters) - Israel-based Pluristem Therapeutics Inc seeks to raise about $32 million from a planned public offering of stock and warrants next week.
Pluristem said on Thursday it has priced 8 million units consisting of one share of the company’s stock and one warrant to purchase 0.35 of a share at $4 each. The offering is expected to close on or about Sept. 19, it said.
Each warrant will be exercisable for a period of five years at an exercise price of $5.00. The company has also granted the underwriters a 30-day option to purchase up to 1.2 million shares of common stock and/or warrants to purchase up to 420,000 shares of common stock to cover over-allotments, if any.
Jefferies & Co is the book-running manager for the offering, with Oppenheimer & Co as co-lead. Needham & Co and Maxim Group are co-managers, while Leader Capital Markets is acting as a financial advisor to the company.
Last month, Pluristem said a second patient suffering from bone marrow failure was saved using its placenta-based stem cell treatment.